Friulchem Logo

Friulchem

CDMO for animal health, providing vet pharma & supplement solutions for pets and livestock.

FCM | XMIL

Overview

Corporate Details

ISIN(s):
IT0005378457 (+1 more)
LEI:
8156003DC8C04217A094
Country:
Italy
Address:
VIA SAN MARCO, 23, 33099 VIVARO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Friulchem is a Contract Development and Manufacturing Organization (CDMO) exclusively dedicated to the animal health sector. The company researches, develops, and manufactures veterinary pharmaceuticals, food supplements, complementary feeds, and premixes for both livestock and pets. Its GMP-authorized services include micronization, granulation, mixing, and spray drying, supported by proprietary drug delivery technologies. Friulchem offers customized formulations and has developed innovative products such as Fc-Cubes®, a highly palatable chewable tablet for pets. Operating on a B2B model, the company provides integrated solutions from development to full-scale manufacturing and packaging at its facilities in Italy and France.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-01-13 18:49
Delisting Announcement
Modulo Dich. Recesso Friulchem SpA
Italian 610.4 KB
2024-12-23 12:22
Delisting Announcement
REVOCA DELL'AMMISSIONE ALLA NEGOZIAZIONE SU EGM DELLE AZIONI EMESSE DALLA SOCIE…
Italian 205.2 KB
2024-12-07 09:58
Pre-Annual General Meeting Information
Friulchem - Avviso Convocazione - v. 08 - DWF - 2024.12.06 - Final
Italian 335.9 KB
2024-12-07 09:57
Delisting Announcement
CS _Convocazione assemblea Revoca_v. 10 - DWF - 2024.12.06 - Final
Italian 185.5 KB
2024-09-29 16:58
Earnings Release
CS APPROVAZIONE RELAZIONE SEMESTRALE CONSOLIDATA FRIULCHEM SPA
Italian 680.5 KB
2024-04-22 17:44
AGM Information
Approvazione assemblea Friulchem - Convocazione assemblea 8 maggio
Italian 283.4 KB
2024-04-05 11:31
Pre-Annual General Meeting Information
AVVISO DI MESSA A DISPOSIZIONE DOCUMENTAZIONE RELATIVA ALL’ASSEMBLEA DEGLI AZIO…
Italian 211.1 KB
2024-04-05 11:30
Pre-Annual General Meeting Information
AVVISO DI CONVOCAZIONE ASSEMBLEA ORDINARIA E STRAORDINARIA 2023
Italian 349.9 KB
2024-04-04 15:02
Pre-Annual General Meeting Information
verifica dei requisiti di indipendenza e convocazione assemblea straordinaria
Italian 113.0 KB
2024-03-22 18:03
Earnings Release
CdA di Friulchem approva il bilancio consolidato e il progetto di bilancio al 3…
Italian 358.5 KB
2024-01-15 15:00
Report Publication Announcement
CALENDARIO EVENTI SOCIETARI 2024
Italian 138.6 KB
2023-09-22 17:36
Earnings Release
IL CONSIGLIO DI AMMINISTRAZIONE DI FRIULCHEM HA APPROVATO LA RELAZIONE CONSOLI…
Italian 965.1 KB
2023-06-08 10:10
Related Party Transaction
FRIULCHEM APPROVA LA DELIBERA QUADRO INERENTE AL CONTRATTO DI FORNITURA DI MATE…
Italian 149.2 KB
2023-04-21 17:16
AGM Information
L’ASSEMBLEA ORDINARIA DEGLI AZIONISTI DI FRIULCHEM
Italian 440.8 KB
2023-04-06 08:28
Pre-Annual General Meeting Information
AVVISO DI CONVOCAZIONE DI ASSEMBLEA ORDINARIA DEGLI AZIONISTI FRIULCHEM S.P.A.
Italian 215.5 KB

Automate Your Workflow. Get a real-time feed of all Friulchem filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Friulchem

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Friulchem via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Cardiol Therapeutics Inc. Logo
Develops oral cannabidiol therapies for inflammatory and fibrotic heart diseases.
United States of America
CRDL
CAREGEN CO.,LTD. Logo
Develops patented peptides and growth factors for medical aesthetics, pharma, and anti-aging markets.
South Korea
214370
Caribou Biosciences, Inc. Logo
Uses CRISPR genome editing to create off-the-shelf CAR-T cell therapies for cancer.
United States of America
CRBU
Carisma Therapeutics Inc. Logo
Developing engineered macrophage (CAR-M) therapies for solid tumors and autoimmune diseases.
United States of America
CARM
Carna Biosciences, Inc. Logo
Develops kinase inhibitor drugs for oncology/autoimmune diseases & offers discovery support services.
Japan
4572
Cartesian Therapeutics, Inc. Logo
Pioneering mRNA-engineered cell therapies to treat autoimmune diseases.
United States of America
RNAC
CASI Pharmaceuticals, Inc. Logo
Develops and commercializes drugs for oncology, transplant, and autoimmune disease.
United States of America
CASI
CATALYST PHARMACEUTICALS, INC. Logo
Advancing therapies for rare neuromuscular and neurological diseases like LEMS.
United States of America
CPRX
cbdMD, Inc. Logo
Produces & distributes lab-tested CBD wellness products for people and pets.
United States of America
YCBD
CDT Equity Inc. Logo
Clinical-stage biopharma using AI to enhance and advance therapies for unmet medical needs.
United States of America
CDT

Talk to a Data Expert

Have a question? We'll get back to you promptly.